P1201: ZANUBRUTINIB PLUS RCHOP(ZR-CHOP) REGIMEN ACHIEVES HIGH COMPLETE RESPONSE RATE IN THE TREATMENT OF NEWLY-DIAGNOSED DOUBLE-EXPRESSION DIFFUSE LARGE B CELL LYMPHOMA

P1201: ZANUBRUTINIB PLUS RCHOP(ZR-CHOP) REGIMEN ACHIEVES HIGH COMPLETE RESPONSE RATE IN THE TREATMENT OF NEWLY-DIAGNOSED DOUBLE-EXPRESSION DIFFUSE LARGE B CELL LYMPHOMA

Bibliographic Details
Main Authors:	Q. He, L. Xie, R. Zhao, J. Ma, C. Liu, C. Chen, H. Wang, K. Lu, J. Li, C. Zhao, N. Shan, L. Xing, Z. Li
Format:	Article
Language:	English
Published:	Wiley 2022-06-01
Series:	HemaSphere
Online Access:	http://journals.lww.com/10.1097/01.HS9.0000847668.08542.45

Similar Items

P1219: ZANUBRUTINIB, LENALIDOMIDE PLUS R-CHOP (ZR2-CHOP) AS THE FIRST-LINE TREATMENT FOR NON-GCB DIFFUSED LARGE B-CELL LYMPHOMA (DLBCL)
by: H. Zhu, et al.
Published: (2022-06-01)

Zanubrutinib plus R-CHOP improves the treatment effect of newly diagnosed diffuse large B cell lymphoma with double expression of MYC and BCL-2
by: Min Zhang, et al.
Published: (2025-03-01)

P1185: ANTITUMOR ACTIVITY AND SAFETY OF ZANUBRUTINIB COMBINED WITH R-CHOP REGIMEN IN THE TREATMENT OF NEWLY DIAGNOSED NON-GCB DLBCL WITH EXTRANODAL INVOLVEMENT: A PROSPECTIVE PHASE II STUDY.
by: C. Li, et al.
Published: (2022-06-01)

P1216: ZANUBRUTINIB PLUS R-CHOP(RI-CHOP) AS THE TREATMENT FOR DOUBLE EXPRESSION OF MYC/BCL2 IN PATIENTS WITH DIFFUSED LARGE B-CELL LYMPHOMA
by: K. Ren, et al.
Published: (2022-06-01)

Clinical trial: Chidamide plus CHOP improve the survival of newly diagnosed angioimmunoblastic T-cell lymphoma
by: Xiangping Zong, et al.
Published: (2024-08-01)

Efficacy and safety of zanubrutinib plus R-CHOP in treatment of non-GCB DLBCL with extranodal involvement
by: Hongzhi Geng, et al.
Published: (2023-08-01)

Characterizing influence of rCHOP treatment on diffuse large B-cell lymphoma microenvironment through in vitro microfluidic spheroid model
by: Matthew R. Sullivan, et al.
Published: (2024-01-01)

Ibrutinib Plus RCHOP versus RCHOP Only in Young Patients with Activated B-Cell-like Diffuse Large B-Cell Lymphoma (ABC-DLBCL): A Cost-Effectiveness Analysis
by: Hayeong Rho, et al.
Published: (2023-12-01)

P1731: IBRUTINIB PLUS RCHOP VERSUS RCHOP ONLY, IN YOUNG PATIENTS WITH ACTIVATED B CELL-LIKE DIFFUSE LARGE B-CELL LYMPHOMA (ABC-DLBCL): A COST EFFECTIVENESS ANALYSIS
by: H. Rho, et al.
Published: (2022-06-01)

Which aggressive B cell lymphoma should not be treated with RCHOP?
by: Christian Gisselbrecht
Published: (2020-10-01)

P1163: ZANUBRUTINIB PLUS RITUXIMAB AND LENALIDOMIDE (ZR2) FOR RELAPSED AND REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA
by: Xiyuan Zhang, et al.
Published: (2023-08-01)

P1185: A PROSPECTIVE SINGLE-CENTER PHASE 2 STUDY OF ZANUBRUTINIB PLUS R-CHOP IN TREAT-NAÏVE INTRAVASCULAR LARGE B CELL LYMPHOMA
by: Yan Zhang, et al.
Published: (2023-08-01)

P1186: RETROSPECTIVE STUDY: ZANUBRUTINIB COMBINED WITH R-CHOP OR R-CHOP REGIMEN IN THE TREATMENT OF UNTREATED NON-GERMINAL CENTER B-CELL SUBTYPE DIFFUSE LARGE B-CELL LYMPHOMA WITH EXTRANODAL INVOLVEMENT.
by: LI Caixia, et al.
Published: (2023-08-01)

Outcome of Primary Mediastinal Large B Cell Lymphoma Treated with RCHOP
by: Halahleh K, et al.
Published: (2023-02-01)

Real-world efficacy of chidamide plus R-CHOP in newly diagnosed double-expressor diffuse large B-cell lymphoma
by: Xi Chen, et al.
Published: (2024-10-01)

Zanubrutinib plus salvage chemotherapy for relapsed or refractory diffuse large B-cell lymphoma
by: Xianggui Yuan, et al.
Published: (2022-11-01)

PB2315: PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA: A RETROSPECTIVE STUDY OF THE ZR OR ZRM REGIMEN (ZANUBRUTINIB, RITUXIMAB, METHOTREXATE)
by: Yue Teng, et al.
Published: (2023-08-01)

P1196: ORIENT STUDY: REGIMEN OF ORELABRUTINIB PLUS R-CHOP-LIKE FOR PATIENTS WITH NEWLY DIAGNOSED UNTREATED NON-GCB DLBCL
by: Chang-Ju Qu, et al.
Published: (2023-08-01)

Targeted agents plus CHOP compared with CHOP as the first-line treatment for newly diagnosed patients with peripheral T-cell lymphoma (GUIDANCE-03): an open-label, multicentre phase 2 clinical trialResearch in context
by: Ming-Ci Cai, et al.
Published: (2024-09-01)

Granisetron plus aprepitant versus granisetron in preventing nausea and vomiting during CHOP or R-CHOP regimen in malignant lymphoma: a retrospective study
by: Yoshinori Wakasugi, et al.
Published: (2019-11-01)

Outcome and patterns of relapse in primary gastric diffuse large B cell lymphoma treated with RCHOP
by: Mohammad Ma'koseh, et al.
Published: (2023-12-01)

P1089: ZANUBRUTINIB-RITUXIMAB CHEMO-FREE THERAPY WITH OR WITHOUT AUTOLOGOUS STEM CELL TRANSPLANTATION IN NEWLY DIAGNOSED MANTLE CELL LYMPHOMA
by: Chang-Ju Qu, et al.
Published: (2023-08-01)

Clinical efficacy and tumour microenvironment influence of decitabine plus R‐CHOP in patients with newly diagnosed diffuse large B‐Cell lymphoma: Phase 1/2 and biomarker study
by: Mu‐Chen Zhang, et al.
Published: (2021-12-01)

PB2097: ZANUBRUTINIB PLUS RITUXIMAB FOR THE TREATMENT OF ELDERLY UNFIT PATIENTS WITH PREVIOUSLY UNTREATED DIFFUSE LARGE-B CELL LYMPHOMA
by: J.-F. Bai, et al.
Published: (2022-06-01)

Comparison of zuberitamab plus CHOP versus rituximab plus CHOP for the treatment of drug-naïve patients diagnosed with CD20-positive diffuse large B-cell lymphoma: a phase 3 trial
by: Hui Zhou, et al.
Published: (2024-10-01)

P1143: ZANUBRUTINIB PLUS CYTARABINE IN PATIENTS WITH REFRACTORY/RELAPSED PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA
by: Zhiguang Lin, et al.
Published: (2023-08-01)

P1242: ZANUBRUTINIB AND RITUXIMAB REGIMEN COMBINED WITH INTRAVITREAL METHOTREXATE FOLLOWED BY ZANUBRUTINIB MAINTENANCE FOR TREAT-NAIVE PRIMARY VITREORETINAL LYMPHOMA: A PROSPECTIVE PHASE II STUDY
by: Y. Zhang, et al.
Published: (2022-06-01)

Identification of a clinicopathologic prognostic index for newly diagnosed large B cell lymphoma patients treated with R-CHOP
by: Vincent Ni, et al.
Published: (2024-11-01)

CHOP-like Regimen in Combination with Rituximab and Peginterferon Alpha-2b in Newly-diagnosed Diffuse Large B-cell Non-Hodgkin’s Lymphoma: Experience in a Chinese Center
by: Shu-qing LV, Jian-min YANG, Xian-min SONG, Li CHEN, Wei-ping ZHANG, Xiao-qian XU, Xiong NI, Chong-mei HUANG, Yi HE, Jian-min WANG, et al.
Published: (2010-04-01)

PB2149: ZANUBRUTINIB IN COMBINATION WITH LENALIDOMIDE AND RITUXIMAB VERSUS R-MINICHOP IN UNFIT OR FRAIL PATIENTS WITH NEWLY DIAGNOSED DIFFUSE LARGE B-CELL LYMPHOMA AGED OVER OR EQUAL TO 70 YEARS
by: P. Xu, et al.
Published: (2022-06-01)

Zanubrutinib in Mantle Cell Lymphoma Management: A Comprehensive Review
by: Alsuhebany N, et al.
Published: (2023-11-01)

A case of cutaneous T cell lymphoma masquerading as keloidal blastomycosis treated with CHOP regimen
by: Duttala Indira Reddy, et al.
Published: (2022-01-01)

NCRI phase II study of CHOP in combination with ofatumumab in induction and maintenance in newly diagnosed Richter syndrome
by: Roberts, C, et al.
Published: (2016)

NCRI phase II study of CHOP in combination with ofatumumab in induction and maintenance in newly diagnosed Richter syndrome
by: Eyre, T, et al.
Published: (2016)

Lenalidomide combined with R-CHOP (R2-CHOP) in the treatment of newly diagnosed double-expressor diffuse large B-cell lymphoma: a prospective phase II clinical trial
by: Yizhen Liu, et al.
Published: (2025-02-01)

Outcome of R-CHOP or CHOP Regimen for Germinal Center and Nongerminal Center Subtypes of Diffuse Large B-Cell Lymphoma of Chinese Patients
by: Ying Huang, et al.
Published: (2012-01-01)

P1201: A REAL-WORLD STUDY OF CHIDAMIDE FOR PATIENTS WITH PERIPHERAL T-CELL LYMPHOMA IN CHINA
by: Xin Wang, et al.
Published: (2023-08-01)

Rapid Remission in Peripheral T-Cell Lymphoma of the Nasal Type by the Bortezomib plus CHOP Therapy
by: Li-Jun Xue, et al.
Published: (2010-01-01)

P1223: PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA: A RETROSPECTIVE STUDY OF THE ZRMA REGIMEN（ZANUBRUTINIB, RITUXIMAB, METHOTREXATE AND CYTARABINE)
by: Y. Tang
Published: (2022-06-01)

Prognostic analysis of CD5 expression in double-hit diffuse large B-cell lymphoma and effectiveness comparison in patients treated with dose-adjusted EPOCH plus rituximab/R-CHOP regimens
by: Zhang F, et al.
Published: (2019-08-01)